Illumina to divest cancer test maker Grail after antitrust battles
Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after battling both U.S. and European antitrust enforcers.
Source link
- ServiceNow dives deeper into task mining with latest acquisition | TechCrunch
- Italy’s demographic crisis worsens despite inflow of foreigners to country
